Table 1.
Summary of all treatment comparisons for age-related macular degeneration, diabetic macular edema, and retinal vein occlusion
| Treatment | Visual acuity (USMD with 95% CI) | Central macular thickness (USMD with 95% CI) | Response to treatment (RR with 95% CI) |
|---|---|---|---|
| Age-related macular degeneration | |||
| Bevacizumab vs PDT19–22 | NA | NA | 3.44 (1.67 to 7.10) |
| Ranibizumab vs bevacizumab23–26 | 0.49 (−1.37 to 2.34) | −14.18 (−32.06 to 3.70) | 0.91 (0.71 to 1.16) |
| Diabetic macular edema | |||
| Bevacizumab vs photocoagulation27–31 | 5.44 (0.05 to 10.83) | 23.61 (−2.78 to 50.00) | 2.40 (1.14 to 5.05) |
| Ranibizumab vs bevacizumab27–30,45–46 | 5.12 (−17.50 to 27.75) | −51.57(−169.84 to 66.69) | 1.02 (0.52 to 1.99)a |
| Retinal vein occlusion | |||
| Bevacizumab vs sham32,47–49 | 8 (−5.26 to 21.26)a | NA | NA |
| Ranibizumab vs sham32,47,48 | 11.39 (9.27 to 13.51) | NA | NA |
| Ranibizumab vs bevacizumab32,47–49 | 3.39 (−10.55 to 17.33)a | NA | NA |
Note:
a
Pooling from network meta-analysis.
Abbreviations: CI, confidence interval; NA, not applicable because of insufficient data for pooling; PDT, photodynamic therapy; RR, relative risk; USMD, unstandardized mean difference.